Compare Viatris Inc (VTRS) vs YieldMax Universe Fund of Option Income ETFs (YMAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Viatris Inc vs YieldMax Universe Fund of Option Income ETFs — how do they compare? Viatris Inc trades at $17.64 (market cap $20.03B), while YieldMax Universe Fund of Option Income ETFs trades at $7.61 (market cap $364M). The key difference: Viatris Inc is far larger — about 55× YieldMax Universe Fund of Option Income ETFs's market cap, and Viatris Inc pays a 2.75% dividend while YieldMax Universe Fund of Option Income ETFs pays none. Which is the better fit depends on your goals — on Pluang, investors hold Viatris Inc for 57 Days and YieldMax Universe Fund of Option Income ETFs for 56 Days on average.
| VTRS | YMAX | |
|---|---|---|
Market Cap | $20.03B | $364M |
Volume | 14,109,977 | 1,181,378 |
Sector | Health | Income / Options Overlay |
52-Week High | $18.27 | $12.98 |
52-Week Low | $9.74 | $7.27 |
Typical Hold Time | 57 Days | 56 Days |
Enterprise Value | $32.15B | — |
Dividend Yield | 2.75% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Viatris (VTRS) trades at $17.44, down 0.29% on the day, with a bullish technical signal from moving averages and oversold short-term RSI. The company reported three consecutive quarterly earnings beats in 2026, with Q2 EPS of $0.69 beating estimates by 14.8%. Revenue for 2025 was $14.3B, though net income was negative $3.51B, reflecting margin pressure. Positive news includes a new drug approval in Japan and recognition as a top employer.
The outlook is mixed: strong cash flow generation and deleveraging support shareholder returns via dividends and buybacks, but profitability challenges and high debt levels pose risks. Analyst consensus is a 'Buy' with a $22.17 price target, implying 27% upside. Investment appeal hinges on execution of pipeline growth and margin improvement amid competitive and pricing pressures in the generics market.
YMAX trades at $7.61, up 1.06% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The ETF maintains a high distribution yield, paying weekly dividends, though recent news highlights concerns about net asset value erosion. Key support is at $7, with resistance at $8.
The outlook is cautious due to structural risks from the fund-of-funds fee structure and declining share price despite distributions. Opportunities exist for income-focused investors seeking high yield, but principal erosion remains a significant risk. Analyst sentiment is neutral to bearish, emphasizing sustainability concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →About YieldMax Universe Fund of Option Income ETFs
YMAX is an actively managed 'fund of funds' that provides equal-weighted exposure to the full suite of YieldMax option income ETFs. It is designed to generate high current income by aggregating the premiums from various single-stock and thematic covered call strategies, offering a diversified approach to high-yield option investing.
Read more on YMAX →
